S. R. Kalla Memorial Gastro & General Hospital Trials

S. R. Kalla Memorial Gastro & General Hospital	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Bossa, Fabrizio

VECTORS, NCT06257706: - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Recruiting

304

Europe, Canada, US, RoW

Vedolizumab

Alimentiv Inc., Takeda

Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn

01/27

09/28

ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting

612

Europe, Canada, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

03/25

04/25

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30

ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting

212

Europe, US, RoW

Obefazimod, Placebo

Abivax S.A.

Moderately to Severely Active Crohn Disease

12/26

04/28

Lee, Bo-In

ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting

612

Europe, Canada, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

03/25

04/25

VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting

778

Europe, Canada, Japan, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company

Crohn's Disease

11/24

12/26

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30

NCT04799496: A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis

Active, not recruiting

N/A

600

RoW

Takeda

Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease

01/26

Gupta, Jugal B

FREEDOM COVID, NCT04512079: -19 Anticoagulation Strategy

Completed

3460

US, RoW

Enoxaparin, Apixaban

Valentin Fuster

COVID-19, SARS-CoV-2

12/22

TRANSCEND-T2D-1, NCT06354660: Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Recruiting

480

US, RoW

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Diabetes Type 2

06/26

07/26

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

09/25

01/26

Kalla, Mukesh

NCT05872269: A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities

Recruiting

1500

RoW

Saroglitazar

Zydus Lifesciences Limited

NAFLD, Obesity, Type 2 Diabetes, Dyslipidemias, Metabolic Syndrome

01/25

06/25

ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting

612

Europe, Canada, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

03/25

04/25

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30

LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis

Recruiting

1063

Europe, Canada, Japan, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company

Ulcerative Colitis

07/26

12/27

Ramakrishna, Balakrishnan S

ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting

612

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

03/25

04/25

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Bossa, Fabrizio

VECTORS, NCT06257706: - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Recruiting

304

Europe, Canada, US, RoW

Vedolizumab

Alimentiv Inc., Takeda

Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn

01/27

09/28

ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting

612

Europe, Canada, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

03/25

04/25

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30

ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting

212

Europe, US, RoW

Obefazimod, Placebo

Abivax S.A.

Moderately to Severely Active Crohn Disease

12/26

04/28

Lee, Bo-In

ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting

612

Europe, Canada, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

03/25

04/25

VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting

778

Europe, Canada, Japan, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company

Crohn's Disease

11/24

12/26

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30

NCT04799496: A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis

Active, not recruiting

N/A

600

RoW

Takeda

Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease

01/26

Gupta, Jugal B

FREEDOM COVID, NCT04512079: -19 Anticoagulation Strategy

Completed

3460

US, RoW

Enoxaparin, Apixaban

Valentin Fuster

COVID-19, SARS-CoV-2

12/22

TRANSCEND-T2D-1, NCT06354660: Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone

Recruiting

480

US, RoW

Retatrutide, LY3437943, Placebo

Eli Lilly and Company

Diabetes Type 2

06/26

07/26

ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting

2749

Europe, US, RoW

Orforglipron, LY3502970, Insulin Glargine

Eli Lilly and Company

Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease

09/25

01/26

Kalla, Mukesh

NCT05872269: A Study to Evaluate the Safety and Effectiveness of Saroglitazar 4 mg in Patients With NAFLD With Comorbidities

Recruiting

1500

RoW

Saroglitazar

Zydus Lifesciences Limited

NAFLD, Obesity, Type 2 Diabetes, Dyslipidemias, Metabolic Syndrome

01/25

06/25

ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting

612

Europe, Canada, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

03/25

04/25

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30

LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis

Recruiting

1063

Europe, Canada, Japan, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company

Ulcerative Colitis

07/26

12/27

Ramakrishna, Balakrishnan S

ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting

612

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

03/25

04/25

ABTECT, NCT05535946: - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

01/30



	Diseases Companies Products Productz Mechanisms of Action Sites